CLAARITYNCT07742839
CLAARITY is a Prospective, Observational, Single-arm, Multi-center, Post-market US Study Designed to Evaluate the Safety and Performance of the ECLIPTIS Left Atrial Appendage Exclusion System for Exclusion of the Left Atrial Appendage (LAA) During Concomitant Open-heart Cardiac Surgery.
StatusNot Yet Recruiting
PhaseNot specified
SponsorEdwards Lifesciences
Primary completion (estimated)
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 2 versions: 2 with changes below. See every version on ClinicalTrials.gov ↗
- Notable Start date: Sep 30, 2026 to Nov 30, 2026
- Eligibility criteria expanded, about 10 words
- Primary endpoints: details revised at 1 of 2 entries
- Secondary endpoints: details revised at 1 of 2 entries
- Study First Submitted
- Notable: the plan changed
Endpoints
Primary
Percentage of participants who have device technical success
Timeframe: Intra-operative
Participant's rate of major clinically significant adverse events
Timeframe: 30 days
Secondary (2)
Percentage of participants who have device technical success
Participant's rate of major clinically significant adverse events over time
Arms and interventions
Edwards ECLIPTIS Left Atrial Appendage Exclusion System
Subjects who were treated with the ECLIPTIS Left Atrial Appendage Exclusion System
Devices: Edwards ECLIPTIS Left Atrial Appendage Exclusion System